Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction

• Published in: International journal of impotence research Vol. 20; no. 4; pp. 388 - 395
• Main Authors: MCCULLOUGH, A. R, STEIDLE, C. P, KAUFMAN, J, GOLDFISCHER, E. R, KLEE, B, CARLSSON, M
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing 01.07.2008; Nature Publishing Group
• Subjects: Adult; Aged; Biological and medical sciences; Complications and side effects; Dosage and administration; Drug therapy; Erectile dysfunction; Erectile Dysfunction - drug therapy; Gynecology. Andrology. Obstetrics; Humans; Impotence; Male; Medical sciences; Middle Aged; Piperazines - adverse effects; Piperazines - therapeutic use; Prognosis; Purines - adverse effects; Purines - therapeutic use; Sexual Behavior - drug effects; Sildenafil; Sildenafil Citrate; Sulfones - adverse effects; Sulfones - therapeutic use; Time Factors; Treatment Outcome; United States; Human; Andrology; Vasodilator agent; Erection disorders; Enzyme; 3',5'-Cyclic-GMP phosphodiesterase; Erection; Sexual dysfunction; Treatment efficiency; Enzyme inhibitor; Male; Esterases; Duration; Phosphoric diester hydrolases; sildenafil citrate; Biological activity; erectile dysfunction; Phosphodiesterase inhibitor; Phosphodiesterase 5 inhibitor; Hydrolases; Adult; Sildenafil; Male genital diseases; duration of activity
• ISSN: 0955-9930; 1476-5489
• DOI: 10.1038/ijir.2008.21

In two randomized, double-blind, placebo-controlled trials of 100 mg sildenafil citrate, men (N=601) with mild to moderate erectile dysfunction (ED) attempted intercourse 8 h (range, 7-9 h) postdose. The baseline to end-of-treatment improvement in the sildenafil groups vs placebo was greater (P<0.001) for the per-patient proportion (PPP) of 'yes' responses to the Sexual Encounter Profile question 3 (SEP3: successful intercourse (primary outcome)) (odds ratio (OR)=3.2 (trial 1), 7.6 (trial 2) and 5.6 (pooled data)); PPP of erection hardness score 4 (EHS 4, completely hard and fully rigid) (OR=6.2 (trial 1) and 10.9 (trial 2)); scores on the International Index of Erectile Function; and other EHS and SEP outcomes. Two to three times as many men were satisfied with sildenafil vs placebo treatment (Erectile Dysfunction Inventory of Treatment Satisfaction Index >50). Thus, responsiveness to 100 mg sildenafil may persist for 8 h postdose in men with mild to moderate ED.